Cilomilast (Ariflo®) does not potentiate the cardiovascular effects of inhaled salbutamol

Pulmonary Pharmacology and Therapeutics

Volumn 15, Issue 6, 2002, Pages 521-527

  Murdoch, Robert D ^a,b   Cowley, H ^a   Kelly, J ^a   Higgins, R ^a   Webber, D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Cell Biology Unit   (United Kingdom)

Author keywords

Asthma; Cilomilast; COPD; PDE4 inhibitors; Salbutamol; 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; SALBUTAMOL; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBOXYLIC ACID; NITRILE; PHOSPHODIESTERASE IV;

ADULT; AGE; ARTICLE; ASTHMA; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; HEALTH STATUS; HEART BEAT; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PULSE RATE; TIME; VOLUNTEER; ADOLESCENT; BLOOD; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG INTERACTION; DRUG POTENTIATION; ELECTROCARDIOGRAPHY; HEART RATE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY, AMBULATORY; HEART RATE; HUMANS; MALE; MIDDLE AGED; NITRILES; RECEPTORS, ADRENERGIC, BETA-2; TIME FACTORS;

EID: 0036941985     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2002.0392     Document Type: Article

References (7)

1. Torphy T J, Barnette M S, Underwood D C, Griswold D E, Christensen S B, Murdoch R D, Nieman R B, Compton C H. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic. Pulmon Pharmacol Ther 1999; 12: 131-135.
2. Beavo J A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple forms. Physiol Rev 1995; 75: 725-748.
3. Barnette M S, Christensen S B, Essayan D M, Grous M, Prabhakar U, Rush J A, Kagey-Sobotka A, Torphy T J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998; 284: 420-426.
4. Christensen S B, Guider A, Forster C J, Gleason J G, Bender P E, Karpinski J M, DeWolf W E, Barnette M S, Underwood D C, Griswold D E, Cieslinski L B, Burman M, Bochnowicz S, Osborn R R, Manning C D, Grous M, Hillegas L M, Bartus J O, Ryan M D, Eggleston D S, Haltwanger R C, Torphy T J. 1,4-Cyclohexane-carboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 1998; 41: 821-835.
5. Torphy T J, Christensen S B, Barnette M S, Burman M, Ceislinski L B, Dewolf W E. Molecular basis for an improved therapeutic index of SB 207499, a second-generation phosphodiesterase 4 inhibitor. Eur Respir J 1997; 10: 313s.
6. Wong C S, Pavord I D, Williams J, Britton J R, Tattersfield A E. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396-1399.
7. Underwood D C, Bochnowicz S, Osborn R R, Kotzer C J, Luttmann M A, Hay D W, Gorycki P D, Christensen S B, Torphy T J. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J Pharmacol Exp Ther 1998; 287: 988-995.